Table 1.
COVID-19–Associated Hospitalized Participants Among Expanded Efficacy Analysis Population.
| Characteristics, n (%) | |
|---|---|
| Total Hospitalized | 12 |
| Trial Placebo Arm | 12 |
| COVID-19 Diagnostic Confirmation | |
| PCR Only | 3 (25%) |
| Rapid Antigen Test Only | 1 (8%) |
| Multiple Test Confirmations | 3 (25%) |
| Diagnostic Assay Confirmed, Unspecified Test | 5 (42%) |
| Severity | |
| Moderate | 3 (25%) |
| Severe | 9 (75%) |
| ICU Admission | |
| Yes | 2 (17%) |
| No/Not reported | 10 (83%) |
| Variant | |
| Alpha | 2 (16%) |
| Iota | 1 (8%) |
| Unknown | 9 (67%) |
| COVID-19 or Pneumonia–Related Hospital Meds | |
| Dexamethasone | 10 (83%) |
| Remdesivir | 10 (83%) |
| Enoxaparin | 6 (50%) |
| Clinical Outcome | |
| Resolved | 11 (91%) |
| Fatal | 1 (8%) |
| Age Range | 48–74 |
| Age Mean ± SD (years) | 58.7 ± 8.2 |
| Age 48–54 | 4 (33%) |
| Age 55–64 | 5 (42%) |
| Age ≥ 65 | 3 (25%) |
| Sex | |
| Female | 5 (42%) |
| Male | 7 (58%) |
| Race/Ethnicity | |
| Black or African American | 2 (17%) |
| White (non-Hispanic or Latino) | 8 (67%) |
| White Hispanic or Latino | 2 (17%) |
| Medical History | |
| Obesity* | 11 (91%) |
| Hypertension | 10 (83%) |
| Hyperlipidemia | 4 (33%) |
| GERD | 2 (17%) |
| Asthma | 1 (8%) |
| Pre-diabetes | 2 (17%) |
| Type I Diabetes | 1 (8%) |
| Type II Diabetes | 2 (17%) |
| COPD | 2 (17%) |
| Depression | 3 (25%) |
| Anxiety | 3 (25%) |
| Total BMI Reported | 9 |
| Mean BMI ± SD kg/m2 | 37.5 (7.6) |
| BMI > 30 kg/m2 (obese) | 2 (22%) |
| BMI > 35 kg/m2 (extremely obese) | 6 (67%) |
BMI, body mass index; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; ICU, intensive care unit; PCR, polymerase chain reaction; SD, standard deviation.
*Obesity was determined by BMI ≥ 30 kg/m2 and/or a reported clinical history of obesity.